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Abstract—This paper presents a comprehensive study of gene
expression patterns originating from a diffuse large B–cell
lymphoma (DLBCL) database. It focuses on the implementation
of feature selection and classiﬁcation techniques. Thus, it ﬁrstly
tackles the identiﬁcation of relevant genes for the prediction
of DLBCL types. It also allows the determination of key
biomarkers to differentiate two subtypes of DLBCL samples:
Activated B–Like and Germinal Centre B–Like DLBCL. Decision
trees provide knowledge–based models to predict types and
subtypes of DLBCL. This research suggests that the data may
be insufﬁcient to accurately predict DLBCL types or even detect
functionally relevant genes. However, these methods represent
reliable and understandable tools for searching interesting non–
linear interdependencies.
I. INTRODUCTION
Lymphomas are divided into two general categories:
Hodgkin’s disease (HD) and non–Hodgkin’s lymphoma
(NHL). Over the past 20 years HD rates have declined,
accounting for only 1% of all cancer. By contrast, NHL cases
have increased by more than 50% during the same period in
the United States [10]. They represent 4% of all cancer cases,
becoming the ﬁfth most common malignancy in that country.
An analysis of NHL incidence trends between 1985 and 1992
in seven European countries showed an average increase of
4.2% per year, in the absence of an increase in the incidence
of HD. In Spain, their death rate per 100.000 people during the
periods 1965–69 and 1995–98 increased 212.7% for men and
283.9% for women [13]. These ﬁgures reveal the signiﬁcance
of developing advanced diagnostic and prognostic systems for
these diseases.
In the last two decades, a better understanding of the
immune system and the genetic abnormalities associated with
NHL have led to the identiﬁcation of several previously unrec-
ognized types of lymphoma. However, this is a complex and
expensive task. For instance, distinctions between Burkitt’s
lymphoma and diffuse large B–cell lymphoma (DLBCL) often
prove to be difﬁcult, since High–grade B–cell Burkitt–like
lymphoma appears to be clinically similar to DLBCL [17].
DLBCL is the most common type of NHL. There are no
reliable morphologicalor immunohistochemicalindicators that
can be used to recognize subtypes of DLBCL. Moreover, it
is fundamental to develop treatments specially tailored to the
individual requirements and proﬁles of patients [9].
Others authors, such as Shipp et al. [16], have studied the
distinction between DLBCL and a related germinal centre B–
cell lymphoma, known as follicular lymphoma (FL), which
over the time acquires morphological and clinical features
observed in DLBCLs.
Technological advances now allow to screen the expression
of thousands of genes in parallel. Thus, gene expression
proﬁling has become crucial for the development of powerful
diagnostic and prognostic methods for these types of cancers.
It offers an opportunityto characterise the biological behaviour
of speciﬁc tumours. Such an approach, which is based on the
use of micro–array techniques, may provide massive amounts
of information. Therefore, there is a need for sophisticated
algorithms capable of extracting novel and useful knowledge
from a biomedical point of view. In fact, gene–expression
proﬁling is thought to be a revolutionary technique to support
the diagnosis of cancers [1].
A basic approach to the study of expression data consists of
applying traditional statistical techniques. In many problems
these methods have shown to be unable to extract relevant
knowledge from data. Thus, the Knowledge Discovery in
Databases approach (KDD) [8] represents a useful framework
for addressing the challenges of gene expression analysis.
In particular, feature selection techniques may signiﬁcantly
support diagnostic studies, based on the identiﬁcation of
relevant genes or biomarkers. Clustering is another important
task within KDD, which aims to organize the information in
terms of their similarity patterns [6]. Supervised classiﬁcation
has also become an important goal in this type of studies [5].
Techniques such as decision trees [4] or decision lists [15] may
represent more effective and understandable tools for aiding
in the prediction of types or subtypes of diseases.
In this paper, we carry out a broad study of a well–known
database generated by Alizadeh et al. [2], who investigated the
identiﬁcation of lymphomas and DLBCL subtypes based on
expression patterns. The data comprise 96 samples described
by the expression values of 4026 genes.
Firstly, feature selection techniques are implemented to
identify relevant genes for the prediction of lymphoma cancer
types. Moreover, it allows the detection of biomarkers to
distinguish two subtypes of DLBCL: Activated B–Like and
Germinal Centre B–Like Lymphomas. The following methods
have been implemented: Information gain criterion, based on
the entropy measure, the Relief method and
￿
2 ranking andTABLE I
MOST RELEVANT GENES PROVIDED BY RELIEF,I NFOGAIN AND
￿
2, ORDERED BY RANKING.
ReliefF Freq. InfoGain Freq.
￿
2 Freq.
GENE1610X
￿
￿
￿ GENE707X
￿
￿ GENE2400X
￿
￿
￿
GENE1636X
￿ GENE655X
￿
￿
￿ GENE788X
￿
￿
GENE1648X
￿ GENE694X
￿
￿
￿ GENE3639X
￿
￿
GENE1622X
￿
￿
￿ GENE1622X
￿
￿
￿ GENE707X
￿
￿
GENE1702X
￿ GENE844X
￿
￿ GENE655X
￿
￿
￿
GENE653X
￿
￿
￿ GENE1635X
￿
￿ GENE1992X
￿
GENE1637X
￿ GENE2400X
￿
￿
￿ GENE1675X
￿
￿
GENE712X
￿
￿ GENE1610X
￿
￿
￿ GENE694X
￿
￿
￿
GENE1607X
￿ GENE717X
￿
￿ GENE3767X
￿
GENE611X
￿ GENE711X
￿ GENE769X
￿
￿
GENE1647X
￿ GENE639X
￿
￿ GENE2387X
￿
￿
GENE708X
￿
￿ GENE2402X
￿
￿ GENE1622X
￿
￿
￿
GENE1651X
￿ GENE769X
￿
￿ GENE1610X
￿
￿
￿
GENE2402X
￿
￿ GENE641X
￿ GENE2032X
￿
GENE537X
￿ GENE628X
￿ GENE467X
￿
￿
GENE1658X
￿ GENE669X
￿ GENE3685X
￿
GENE654X
￿
￿ GENE2403X
￿
￿
￿ GENE2403X
￿
￿
￿
GENE1608X
￿ GENE647X
￿ GENE1371X
￿
GENE2393X
￿ GENE712X
￿
￿ GENE2033X
￿
GENE1641X
￿ GENE783X
￿
￿ GENE646X
￿
￿
GENE721X
￿ GENE653X
￿
￿
￿ GENE753X
￿
￿
￿
GENE651X
￿
￿ GENE691X
￿ GENE783X
￿
￿
GENE1644X
￿ GENE753X
￿
￿
￿ GENE764X
￿
GENE1635X
￿
￿ GENE2495X
￿ GENE639X
￿
￿
GENE753X
￿
￿
￿ GENE651X
￿
￿ GENE2428X
￿
ReliefF Freq. InfoGain Freq.
￿
2 Freq.
GENE717X
￿
￿ GENE467X
￿
￿ GENE2202X
￿
GENE2403X
￿
￿
￿ GENE646X
￿
￿ GENE2199X
￿
￿
GENE2270X
￿ GENE3639X
￿
￿ GENE844X
￿
￿
GENE784X
￿ GENE2395X
￿
￿ GENE777X
￿
￿
GENE2486X
￿ GENE2668X
￿
￿ GENE654X
￿
￿
GENE1603X
￿ GENE788X
￿
￿ GENE1990X
￿
GENE2489X
￿ GENE1672X
￿ GENE2424X
￿
￿
GENE703X
￿ GENE2379X
￿ GENE276X
￿
GENE692X
￿ GENE770X
￿
￿ GENE2862X
￿
GENE2271X
￿ GENE648X
￿ GENE794X
￿
GENE2401X
￿ GENE642X
￿ GENE770X
￿
￿
GENE1653X
￿ GENE593X
￿ GENE768X
￿
GENE1646X
￿ GENE1606X
￿ GENE2778X
￿
GENE2244X
￿ GENE734X
￿ GENE3764X
￿
GENE694X
￿
￿
￿ GENE604X
￿ GENE2395X
￿
￿
GENE655X
￿
￿
￿ GENE777X
￿
￿ GENE2374X
￿
￿
GENE538X
￿ GENE1673X
￿ GENE1324X
￿
GENE731X
￿ GENE2374X
￿
￿ GENE1343X
￿
GENE2668X
￿
￿ GENE2199X
￿
￿ GENE2795X
￿
GENE584X
￿ GENE649X
￿ GENE653X
￿
￿
￿
GENE1776X
￿ GENE708X
￿
￿ GENE1320X
￿
GENE713X
￿ GENE1675X
￿
￿ GENE3334X
￿
GENE2400X
￿
￿
￿ GENE2387X
￿
￿ GENE2000X
￿
GENE710X
￿ GENE2424X
￿
￿ GENE473X
￿
GENE714X
￿ GENE706X
￿ GENE1323X
￿
ﬁltering. Decision trees are constructed to perform classiﬁca-
tion tasks initially based on the original classes, and afterwards
using the DLBCL subtypes.
This study reveals that not only the genes identiﬁed by
Alizadeh et al. are relevant for the prediction of the two
subtypes of DLBCL, but many others groups may also be
considered as relevant markers. In general, KDD techniques
demonstrate to be efﬁcient for extracting valid and useful
knowledge from biomedical data.
II. FEATURE SELECTION FOR GENE EXPRESSION DATA
Feature subset selection is the process of identifying and
removing irrelevant or redundant attributes. Decreasing the
dimensionality of the data reduces the size of the hypothesis
space and allows learning algorithms to operate faster and
more effectively. It leads to smaller and easy–to–understand
knowledge models of the target concept. Feature selection
techniques produce ranked lists of attributes, providing the
data analyst with insight into their data by clearly demonstrat-
ing the relative merit of individual attributes.
In this study, we used three feature selection techniques,
both belonging to the ﬁlter category [7], Information Gain
Attribute Ranking, ReliefF [11], [12] and
￿
2 [14]. The in-
formation gain attribute ranking is often used where the
sheer dimensionality of the data precludes more sophisticated
attribute selection techniques, as the case being investigated
here, which consist of 4026 attributes. ReliefF works by
randomly sampling an instance from the data and then lo-
cating its nearest neighbour from the same and a different
class. When dealing with noisy data the k nearest neighbours
should be obtained. If the data contains multiple classes, the
contributions of the k nearest neighbours can be weighted
using the prior probabilities associated with each class. The
values of the attributes of the nearest neighbours are compared
to the sampled instance and used to update relevance scores
for each attribute. The rationale is that a useful attribute should
differentiate instances from different classes, and has the same
value for instances belonging to the same class.
￿
2 statistic
conducts a signiﬁcance test on the relationship between the
values of an attribute and the classes.
This study presents results based on the original set of genes
(4026), and on a subset of 50 relevant genes extracted from
them, in order to compare our result to that identiﬁed by
Alizadeh et al. [2].
A. Lymphoid malignancies
The three methods provided different results and they were
compared to ﬁnd coincidences. Table I shows the genes
selected by each method, and ordered by their relevance from
top to bottom. The genes are represented with the identiﬁers
used by Alizadeh et al. Figure 1 provides the gene names
associated with each identiﬁer. We found 8 common genes for
the three methods, 25 common pairs of genes and 76 genes
that were selected by only one method. Note that there are
105 different genes in Table I, from 150 possible selections.
Figure 1 shows these genes in terms of degrees of relevance:
Very high and high relevance. Very highly relevant genes are
those which have been selected by all of the feature selection
methods. Highly relevant genes are those which have been
identiﬁed by any two of the methods. In total, there are 8
very highly relevant genes and 25 highly relevant genes.
The next task is to know whether these 8 very highly
relevant genes or, in the worst case, the 33 genes including
the highly relevant ones, can predict a cancer class. This will
be shown using decision trees in section III. Alizadeh et al.
discovered 50 relevant genes to differentiate the GC B–Like
from the Activated B–Like subtypes of DLBCL. However,      ID Name
GENE653X Lactate dehydrogenase A
GENE655X GRSF-1=cytoplasmic G-rich mRNA sequence binding factor
GENE694X Cyclin A
GENE753X Similar to MCM2 = DNA replication licensing factor
GENE2400X Unknown
GENE2403X Unknown
GENE1610X Mig=Humig=chemokine targeting T cells
GENE1622X CD63 antigen (melanoma 1 antigen)
GENE467X C-1-Tetrahydrofolate Synthase, cytoplasmic
GENE639X hepatoma-derived growth factor
GENE646X nm23-H2=NDP kinase B=Nucleoside dephophate kinase B
GENE651X tubulin-beta
GENE654X dystrobrevin B DTN-B2=dystrophin-associated protein A0
GENE707X Topoisomerase II alpha (170kD)
GENE708X Ki67 (long type)
GENE712X Cyclin B1
GENE717X aurora/IPL1-related kinase
GENE769X 14-3-3 epsilon
GENE770X 14-3-3 epsilon
GENE777X semaphorin V=homologue of nerve growth cone guidance signaling proteins
GENE783X Glycyl tRNA synthetase
GENE788X SRPK1=serine kinase
GENE844X ets-2=ets family transcription factor
GENE1635X osteonectin=SPARC=basement membrane protein
GENE1675X FCERI=Fc epsilon receptor gamma chain=High affinity immunoglobulin epsilon receptor gamma
GENE2199X Unknown  UG Hs.71252  ESTs
GENE2374X PKC beta =Protein kinase C, beta
GENE2387X Unknown  UG Hs.181297  ESTs
GENE2395X Unknown  UG Hs.59368  ESTs
GENE2402X Unknown
GENE2424X Similar to neuropathy target esterase
GENE3639X KIAA0053
GENE2668X Mad2=MXI-1=MAX-binding protein=antagonizer of myc transcriptional activity=
                                    =Mxi-1/Max heterodimers repress c-myc targets
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Fig. 1. Relevant genes to differentiate the lymphoma classes from the complete dataset (96 patients and 4026 attributes). The 50 most relevant genes for
each feature selection method were selected. very highly relevant means that the gene was relevant for the three methods; highly relevant means that it was
relevant for any two methods. There is no order of relevance in the list.
only one of them, GENE2395X, has been identiﬁed in our
analysis.
It is important to note that several attributes are strongly
correlated with others (Pearson’s correlation coefﬁcient greater
than 0.90), even among those genes selected as very highly or
highly relevant in Figure 1. This fact shows that most methods
for feature selection do not take into account the correlation
among extracted features. Therefore, this information needs
to be post–processed, removing genes of similar functionality.
For instance, GENE769X and GENE770X, shown in Figure 1,
or GENE1719X and GENE1720X, in Figure 2.
B. DLBCL subtypes
In this section the 45 DLBCL samples are analysed. This
category is divided into to subtypes: Activated B–like DLBCL
(ACL) and Germinal Centre B–like DLBCL (GCL). Among
these 45 examples, 22 belong to class GCL and 23 to class
ACL.
The Relief algorithm, InfoGain and
￿
2 methods have been
applied to select the most relevant attributes to differentiate
these sub–classes. These methods provided 25 common at-
tributes, which will be considered as very high relevant, and
they are enumerated in Figure 2.
Figures 1 and 2 do not include genes in common. It
suggests that the genes required to differentiate among types
of lymphoma cancer may be different to those distinguishing
DLBCL subtypes. Nevertheless, several genes which experts
had identiﬁed as having some functionality associated with
lymphoma, are present in the subset, among them, TTG–2
and CD10. Furthermore, others like MCL1, JNK3 or FMR2,
have not been linked to DLBCL.
III. DECISION TREES
Decision trees are a useful technique in the context of
supervised learning. They perform classiﬁcation by a sequence
of tests whose semantics are intuitively clear and easy to
understand. Some tools, like J48, construct decision trees
selecting the best attribute by using a statistical test to deter-
mine how well it alone classiﬁes the training examples. Our
experiments were performed by using the WEKA library for
machine learning [18].
To avoid over–estimating the prediction accuracy that occurs
when a model is trained and evaluated with the same samples,
the “leave–one–out” testing method has been used. In this
case 96–fold cross–validation and 45–fold cross–validation
procedures are implemented when the lymphoma types and
DLBCL subtypes are analysed respectively.      ID Name
GENE1296X MCL1=myeloid cell differentiation protein
GENE1719X TTG-2=Rhombotin-2=translocated in t(11;14)(p13;q11) T cell acute lymphocytic leukemia=cysteine rich protein with LIM motif
GENE1720X TTG-2=Rhombotin-2=translocated in t(11;14)(p13;q11) T cell acute lymphocytic leukemia=cysteine rich protein with LIM motif
GENE3228X JNK3=Stress-activated protein kinase
GENE3254X Unknown  UG Hs.145058  ESTs
GENE3255X Unknown
GENE3256X JAW1=lymphoid-restricted membrane protein
GENE3258X JAW1=lymphoid-restricted membrane protein
GENE3259X Unknown  UG Hs.124922  ESTs
GENE3261X Unknown
GENE3314X Unknown
GENE3315X FMR2=Fragile X mental retardation 2=putative transcription factor=LAF-4 and AF-4 homologue
GENE3318X CD10=CALLA=Neprilysin=enkepalinase
GENE3325X Unknown  UG Hs.120245  Homo sapiens mRNA for KIAA1039 protein, partial cds
GENE3326X Unknown  UG Hs.105261  EST
GENE3327X Unknown  UG Hs.169565  ESTs, Moderately similar to !!!! ALU SUBFAMILY SB WARNING ENTRY !!!! [H.sapiens]
GENE3328X Unknown  UG Hs.136345  ESTs
GENE3329X Unknown  UG Hs.224323  ESTs, Moderately similar to alternatively spliced product using exon 13A [H.sapiens]
GENE3330X Unknown
GENE3331X Unknown  UG Hs.208410  EST, Moderately similar to !!!! ALU SUBFAMILY SB WARNING ENTRY !!!! [H.sapiens]
GENE3332X Unknown  UG Hs.120716  ESTs
GENE3335X myb-related gene A=A-myb
GENE3355X Unknown
GENE3939X Unknown  UG Hs.169081  ets variant gene 6 (TEL oncogene)
GENE3968X Deoxycytidylate deaminase
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Fig. 2. Relevant genes to differentiate Activated B–like DLBCL from Germinal Centre B–like DLBCL (45 patients and 4026 attributes). The 50 most relevant
genes for each feature selection method were selected. There is no order of relevance in the list.
GENE1602X <= -0.44
| GENE2426X <= 0.59
| | GENE3959X <= 0.33: FL
| | GENE3959X > 0.33: GCB
| GENE2426X > 0.59: CLL
GENE1602X > -0.44
| GENE563X <= -0.52
| | GENE3701X <= -1.2: RAT
| | GENE3701X > -1.2: RBB
| GENE563X > -0.52
| | GENE717X <= -0.5: ABB
| | GENE717X > -0.5
| | | GENE694X <= 1.54: DLBCL
| | | GENE694X > 1.54: TCL
Tree Size = 15
Number of genes = 7 (from 4026)
Training Error = 2.08%
96-Fold CV Error = 20.84%
(a)
GENE646X <= -0.61
| GENE844X <= -1.02: CLL
| GENE844X > -1.02
| | GENE2387X <= -0.68: RAT
| | GENE2387X > -0.68
| | | GENE2374X <= 0.61: FL
| | | GENE2374X > 0.61: RBB
GENE646X > -0.61
| GENE717X <= -0.5
| | GENE3639X <= -0.28: NIL
| | GENE3639X > -0.28: ABB
| GENE717X > -0.5
| | GENE694X <= 1.54
| | | GENE2402X <= 1.45: DLBCL
| | | GENE2402X > 1.45: FL
| | GENE694X > 1.54: TCL
Tree Size = 17
Number of genes = 8 (from 33)
Training Error = 5.38%
96-Fold CV Error = 26.05%
(b)
GENE1622X <= -1.17
| GENE753X <= 0.61
| | GENE753X <= -0.88
| | | GENE653X <= -2.24: CLL
| | | GENE653X > -2.24
| | | | GENE655X <= -1.34: RBB
| | | | GENE655X > -1.34: CLL
| | GENE753X > -0.88: FL
| GENE753X > 0.61
| | GENE694X <= 0.6: RAT
| | GENE694X > 0.6
| | | GENE2403X <= 0.06: DLBCL
| | | GENE2403X > 0.06: GCB
GENE1622X > -1.17
| GENE694X <= -0.83: ABB
| GENE694X > -0.83
| | GENE694X <= 1.54
| | | GENE1610X <= -0.79: ABB
| | | GENE1610X > -0.79: DLBCL
| | GENE694X > 1.54: TCL
Tree Size = 21
Number of genes = 7 (from 8)
Training Error = 6.79%
96-Fold CV Error = 19.80%
(c)
Fig. 3. Decision trees to differentiate lymphoma classes. All of the decision trees were generated using 96 patients. In (a) 4026 genes were used (the whole
set); in (b) 33 genes (very high and high relevant); and in (c) only 8 genes (very high relevant). Labels were assigned to each type of lymphoma cancer,
based on the study by Alizadeh et al.: Diffuse large B–cell lymphoma (DLBCL), Germinal centre B (GCB), NI. lymphoma node/tonsil (NIL), Activated blood
B(ABB), Resting/activated T (RAT), Transformed cell lines (TCL), Follicular lymphoma (FL), Resting blood B (RBB) and Chronic lymphocytic leukaemia
(CLL).
A. Prediction of lymphoid malignancies
Three decision trees were generated to differentiate among
types of lymphoma. The ﬁrst decision tree algorithm (Fig-
ure 3a) used the complete set of genes as input. However, the
resulting tree comprises only 7 genes, producing an error rate
of 2.08% (training set as test set), and 20.84% (leave–one–out
method). The second decision tree (Figure 3b) selected 8 genes
among the 33 genes extracted by the feature selection methods,
making an error rate of 5.28% (training) and 26.05% (leave–
one–out). The third decision tree (Figure 3c) provides an errorGENE3330X <= 0.38
| GENE518X <= -0.23: GCL
| GENE518X > -0.23: ACL
GENE3330X > 0.38: GCL
Tree Size = 5
Number of genes = 2 (from 4026)
Training Error = 2.23%
45-Fold CV Error = 17.78%
(a)
GENE3330X <= 0.38
| GENE3939X <= -0.82: GCL
| GENE3939X > -0.82: ACL
GENE3330X > 0.38: GCL
Tree Size = 5
Number of genes = 2 (from 25)
Training Error = 2.43%
45-Fold CV Error = 17.78%
(b)
GENE3330X <= 0.38
| GENE3512X <= -0.61: GCL
| GENE3512X > -0.61: ACL
GENE3330X > 0.38: GCL
Tree Size = 5
Number of genes = 2 (from 2)
Training Error = 2.23%
45-Fold CV Error = 8.89%
(c)
Fig. 4. Decision trees for DLBCL sub-classes. All of the decision trees were generated using 45 patients. In (a) 4026 genes were used (the whole set); in
(b) 25 genes (very high relevant); and in (c) only 2 genes (1 was randomly chosen from the data).
rate of 6.79% (training) and 19.80% (leave–one–out). Thus,
from a prediction point of view, only those genes categorized
as very higly relevant allow the generation of the best decision
trees.
The gene GENE694X (cyclin A) seems to be decisive in the
prediction of lymphoma types, as it is the only one that appears
in all of the decision trees. In the ﬁrst one, differentiates
DLBCL from TCL; in the second one, DLBCL and FL from
TCL; and in the third one, RAT from DLBCL and GCB, and
ABB and TCL from DLBCL (although the gen GENE1610X
plays an important role to separate ABB from DLBCL). This
machine learning method has remarkably recognised a key
gene, which has been previously linked to the process of
cell proliferation. Furthermore, a high protein expression of
cyclin A has been associated with prognosis outcomes in non-
Hodgkin’s lymphomas [19].
B. Prediction of DLBCL subtypes
Figure 4 illustrates three decision trees generated to differen-
tiate among the DLBCL subtypes, ACL and GCL. Two genes
were sufﬁcient to build the trees. The gene GENE3330X has
been included in all of the trees, which indicates its relevance
to achieve this classiﬁcation.
However, this gene can be combined with many others
without considerably increasing the error rate. In fact, we
randomly selected an a priori non–relevant gene, the gene
GENE3512X, and the error rate was even lower than earlier,
about 8.8% (leave–one–out). Therefore, one may state that the
difference among the more important genes in terms of their
relevance is very slight.
Based on medical research about the signiﬁcance of speciﬁc
genes to differentiate subtypes of DLBCL, 5 genes have
been selected. They are those encoding CD10 (GENE3317X,
GENE3318X and GENE3319X), BCL–6 (GENE3340X and
GENE3341X), TTG–2 (GENE1719X and GENE1720X),
IRF–4 (GENE1212X and GENE1213X) and BCL–2 (GE-
NE2514X, GENE2536X, GENE2537X, GENE2538X), and
some genes belonging to the BCL–2 family (GENE385X,
GENE386X, GENE387X, GENE3619X and GENE3620X).
The importance of these genes has been demonstrated by
Azuaje by means of the simpliﬁed fuzzy ARTMAP model,
which is a neural network–based model [3].
Results provided by the decision tree used only four genes
(GENE1719X, GEN3318X, GENE3340X and GENE385X)
and the error rate was 0% (training) and 26.67% (leave–
one–out). The overﬁtting was very high, and therefore, these
genes are not appropriate to predict accurately the subtype of
DLBCL by using a decision tree.
IV. CONCLUSIONS
A broad study of the database generated by Alizadeh et
al. [2] was presented in this paper. It focused on both the
feature selection and classiﬁcation tasks.
From a biomedical point of view, the relevance of speciﬁc
genes reported by Alizadeh et al. is not observed in our
results. This is perhaps because other genes may also play
an important role in processes associated with this disease.
However, this conclusion may not be strongly supported by
results, as these have been obtained from a small amount of
patients, in comparison to the number of genes.
These analyses indicate that the data are insufﬁcient to state
indisputable conclusions. Many subsets of genes can achieve
a good prediction performance, although most of them would
provide an overﬁtted decision tree. From a classiﬁcation point
of view, some genes are indeed very important, but more data
should be included to support these observations. Alizadeh et
al. inferred that a subset of genes could accurately differentiate
among two subtypes of DLBCL. Nevertheless, none of such
subsets have been identiﬁed by our KDD framework. The
results also suggest that several subsets can attain the same
classiﬁcation aims. In fact, many decision trees can be built
by using non–identiﬁed–as–relevant genes, producing similar
error rates for the classiﬁcation task. Furthermore,this research
indicates that a deep study on the non–linear inter–relationship
among genes might reveal interesting properties, as it has been
discussed in [3]. With regard to the analysis of non–linear
inter–relationships among genes for distinguishing lymphoma
subtypes, we have recently built a neural network classiﬁer
based on 25 genes selected by the Relief method (with 3
nearest neighbours). This model, which consisted of two
hidden layers and was tested with 45–fold cross–validation,
produced an error rate equal to 0%.
The bioinformatics ﬁeld is wide and requires an interdis-
ciplinary action between the life and computer sciences. The
amount of data is huge and rapidly growing. This type of
collaboration is essential to achieve scientiﬁc and health goals.
We are currently interested in two speciﬁc aspects of bioin-
formatics: a) the development of algorithms to accelerate the
identiﬁcation of useful knowledge from biomedical databases,and b) the appropriate and methodical application of existing
data mining techniques to produce understandable knowledge
models for domain experts.
This study highlights the importance of data mining tech-
niques to extract interesting patterns from biological data, the
signiﬁcance of the results in contrast to statistics, and their
future projection.
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